Abstract:Background Lowering intraocular pressure (IOP) is currently the only therapeutic approach in primary open-angle glaucoma. and the fixed-combination medications are needed to achieve sufficiently low target IOP. A multicenter prospective study in the Chinese population was needed to confirm the safety and efficacy of Bimatoprost/Timolol Fixed Combination Eye Drop in China. In this study, we evaluated the safety and efficacy of Bimatoprost/Timolol Fixed Combination with concurrent administration of its components in Chinese patients with open-angle glaucoma or ocular hypertension. Methods In this multicenter, randomized, double-masked, parallel controlled study, patients with open-angle glaucoma or ocular hypertension who were insufficiently responsive to monotherapy with either topical β-blockers or prostaglandin analogues were randomized to one of two active treatment groups in a 1:1 ratio at 11 Chinese ophthalmic departments. Bimatoprost/timolol fixed combination treatment was a fixed combination of 0.03% bimatoprost and 0.5% timolol (followed by vehicle for masking) once daily at 19:00 P.M. and concurrent treatment was 0.03% bimatoprost followed by 0.5% timolol once daily at 19:00 P.M. The primary efficacy variable was change from baseline in mean diurnal intraocular pressure (IOP) at week 4 visit in the intent-to-treat (ITT) population. Primary analysis evaluated the non-inferiority of bimatoprost/timolol fixed combination to concurrent with respect to the primary variable using a confidence interval (CI) approach. Bimatoprost/timolol fixed combination was to be considered non-inferior to concurrent if the upper limit of the 95% CI for the between-treatment (bimatoprost/timolol fixed combination minus concurrent) difference was ≤1.5 mmHg. Adverse events were collected and slit-lamp examinations were performed to assess safety. Between-group comparisons of the incidence of adverse events were performed using the Pearson chi-square test or Fisher's exact test. Results Of the enrolled 235 patients, 121 patients were randomized to receive bimatoprost/timolol fixed combination and, 114 patients were randomized to receive concurrent treatment. At baseline the mean value of mean diurnal IOP was (25.20±3.06) mmHg in the bimatoprost/timolol fixed combination group and (24.87±3.88) mmHg in the concurrent group. The difference between the treatment groups was not statistically significant. The mean change from baseline in mean diurnal IOP (±standard deviation) in the bimatoprost/timolol fixed combination group was (−9.38±4.66) mmHg and it was (−8.93±4.25) mmHg in the concurrent group (P <0.01). The difference between the two treatment groups (bimatoprost/timolol fixed combination minus concurrent) in the change from baseline of mean diurnal IOP was -0.556 mmHg (95% CI: −1.68, 0.57, P=0.330). The upper limit of the 95% CI was less than 1.5 mmHg, the predefined margin of non-inferiority. Adverse events occurred in 26.4% (32/121) of the bimatoprost/timolol fixed combination patients and 30.7% (35/114) of the concurrent patients. The most frequent adverse event was conjunctival hyperemia, which was reported as treatment related in 16.5% (20/121) in the bimatoprost/timolol fixed combination group and 18.4% (21/114) in the concurrent group (P >0.05). Conclusions Bimatoprost/Timolol Fixed Combination administered in Chinese patients with open-angle glaucoma or ocular hypertension was not inferior to concurrent dosing with the individual components. Safety profiles were similar between the treatment groups.

The Efficacy and Safety Associated with Switching from Concomitant Brimonidine and Ripasudil, or Brimonidine or Ripasudil Monotherapy to a Fixed Combination of Brimonidine and Ripasudil in Glaucoma Patients

Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study

Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil

Effect of a fixed combination of ripasudil and brimonidine on aqueous humor dynamics in mice

Comparison of Latanoprost and Brimonidine in the Treatment of Open Angle Glaucoma

Brinzolamide plus brimonidine for the treatment of glaucoma: an update

Drug combination of topical ripasudil and brimonidine enhances neuroprotection in a mouse model of optic nerve injury

Comparison of allergy prevalence using brinzolamide 1.0% / brimonidine 0.2% fixed combination with and without β-blocker in glaucoma patients: a retrospective cohort study

Efficacy and Safety of Netarsudil/latanoprost Fixed-Dose Combination Vs. Monotherapy in Open-Angle Glaucoma or Ocular Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

The effectiveness of transferring patients with open-angle glaucoma to therapy with a preservative-free fixed combination of a carbonic anhydrase inhibitor and a prostaglandin analogue

Preservative-free Bimatoprost 0.01% Ophthalmic Gel for Glaucoma Therapy. A Phase III Randomized Controlled Trial

Clinical Investigation:The Intraocular Pressure-lowering Efficacy and Safety of Brinzolamide Combined with Betaxolol

Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil

Comparison of a preservative‐free bimatoprost 0.01% ophthalmic gel with a preserved bimatoprost 0.01% ophthalmic solution: A phase III, randomized, multicentre, 3‐month study

[The Ocular Hypotensive Effect and Safety of 0.2% Brimonidine].

Sustained Release of Brimonidine from Polydimethylsiloxane-Coating Silicone Rubber Implant to Reduce Intraocular Pressure in Glaucoma.

A 12-Week, Double-Masked, Parallel-Group Study of the Safety and Efficacy of Travoprost 0.004% Compared with Pilocarpine 1% in Chinese Patients with Primary Angle-Closure and Primary Angle-Closure Glaucoma

Safety and Efficacy of Bimatoprost/timolol Fixed Combination in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension.

Efficacy of brinzolamide in the initial management of acute primary angle closure: A randomized controlled trial

Sustained release of brimonidine from conjunctival sac insert to reduce intraocular pressure for glaucoma treatment

The Protective Effect of Rho-Associated Kinase Inhibitor Eye Drops (Ripasudil) on Corneal Endothelial Cells After Cataract Surgery: A Prospective Comparative Study